135 related articles for article (PubMed ID: 7053270)
21. N-(phosphonacetyl)-L-aspartate (PALA) in advanced breast cancer: a phase II trial of the EORTC breast cancer cooperative group.
Paridaens R; Mouridsen HT; Palshof T; Cocconi G; Van Oosterom A; Rotmensz N; Sylvester R; Heuson JC; Rozencweig M
Eur J Cancer Clin Oncol; 1982 Jan; 18(1):67-70. PubMed ID: 6211361
[TBL] [Abstract][Full Text] [Related]
22. Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside (MMPR), and leucovorin in patients with advanced cancer.
Hageboutros A; Hudes GR; Greene F; LaCreta FP; Brennan J; O'Dwyer PJ
Invest New Drugs; 1997; 15(2):139-45. PubMed ID: 9220293
[TBL] [Abstract][Full Text] [Related]
23. Phase I-II clinical trial of thymidine, 5-FU, and PALA given in combination.
Chiuten DF; Valdivieso M; Bedikian A; Bodey GP; Freireich EJ
Cancer Treat Rep; 1985 Jun; 69(6):611-3. PubMed ID: 4016768
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic utility of utilizing low doses of N-(phosphonacetyl)-L-aspartic acid in combination with 5-fluorouracil: a murine study with clinical relevance.
Martin DS; Stolfi RL; Sawyer RC; Spiegelman S; Casper ES; Young CW
Cancer Res; 1983 May; 43(5):2317-21. PubMed ID: 6187448
[TBL] [Abstract][Full Text] [Related]
25. Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer.
Rosvold E; Schilder R; Walczak J; DiFino SM; Flynn PJ; Banerjee TK; Heim WJ; Engstrom PF; Ozols RF; O'Dwyer PJ
Cancer Chemother Pharmacol; 1992; 29(4):305-8. PubMed ID: 1537077
[TBL] [Abstract][Full Text] [Related]
26. Chemotherapeutic strategies in metastatic colorectal cancer: an overview of current clinical trials.
Köhne-Wömpner CH; Schmoll HJ; Harstrick A; Rustum YM
Semin Oncol; 1992 Apr; 19(2 Suppl 3):105-25. PubMed ID: 1373004
[TBL] [Abstract][Full Text] [Related]
27. PALA in advanced breast cancer. A phase II pilot study by the ECOG.
Taylor SG; Davis TE; Falkson G; Keller AM
Am J Clin Oncol; 1982 Dec; 5(6):627-9. PubMed ID: 7165004
[TBL] [Abstract][Full Text] [Related]
28. Phase I study of continuous-infusion PALA and 5-FU.
Ardalan B; Jamin D; Jayaram HN; Presant CA
Cancer Treat Rep; 1984 Mar; 68(3):531-4. PubMed ID: 6231102
[TBL] [Abstract][Full Text] [Related]
29. A comparative study of PALA, PALA plus 5-FU, and 5-FU in advanced breast cancer.
Mann GB; Hortobagyi GN; Buzdar AU; Yap HY; Valdivieso M
Cancer; 1985 Sep; 56(6):1320-4. PubMed ID: 4027872
[TBL] [Abstract][Full Text] [Related]
30. Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside.
Hageboutros A; Hudes GR; Brennan J; Green F; Hoffman J; LaCreta FP; Colofiore J; Martin DS; Ozols RF; O'Dwyer PJ
Cancer Chemother Pharmacol; 1996; 37(3):229-34. PubMed ID: 8529282
[TBL] [Abstract][Full Text] [Related]
31. Biochemical modulation of 5-fluorouracil by PALA.
O'Dwyer PJ
Cancer Invest; 1990; 8(2):261-2. PubMed ID: 2400945
[No Abstract] [Full Text] [Related]
32. Plasma uridine changes in cancer patients treated with the combination of dipyridamole and N-phosphonacetyl-L-aspartate.
Chan TC; Markman M; Cleary S; Howell SB
Cancer Res; 1986 Jun; 46(6):3168-72. PubMed ID: 3698032
[TBL] [Abstract][Full Text] [Related]
33. Antitumor activity of N-phosphonacetyl-L-aspartic acid in combination with nitrobenzylthioinosine.
Erlichman C; Vidgen D
Biochem Pharmacol; 1984 Oct; 33(20):3177-81. PubMed ID: 6487365
[TBL] [Abstract][Full Text] [Related]
34. Initial clinical study with N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with advanced cancer.
Hart RD; Ohnuma T; Holland JF
Cancer Treat Rep; 1980; 64(4-5):617-24. PubMed ID: 6448687
[TBL] [Abstract][Full Text] [Related]
35. A Phase I study of the combination N-(phosphonacetyl)-L-aspartate (PALA, NSC-224131) and L-alanosine (NSC-153353) in patients with advanced cancer.
Creagan ET; O'Connell MJ; Kovach JS
Cancer; 1983 Aug; 52(4):615-8. PubMed ID: 6861099
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of PALA and AMSA in advanced renal cell carcinoma.
Earhart RH; Elson PJ; Rosenthal SN; Hahn RG; Slayton RE
Am J Clin Oncol; 1983 Oct; 6(5):555-60. PubMed ID: 6688498
[TBL] [Abstract][Full Text] [Related]
37. Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate in patients with advanced colorectal cancer. Results of a phase II study.
Köhne CH; Harstrick A; Hiddemann W; Schöffski P; Wilke H; Bokemeyer C; Dörken B; Schmoll HJ
Eur J Cancer; 1997 Oct; 33(11):1896-9. PubMed ID: 9470854
[TBL] [Abstract][Full Text] [Related]
38. Clinical trial of sequential N-phosphonacetyl-L-aspartate, thymidine, and 5-fluorouracil in advanced colorectal carcinoma.
O'Connell MJ; Moertel CG; Rubin J; Hahn RG; Kvols LK; Schutt AJ
J Clin Oncol; 1984 Oct; 2(10):1133-8. PubMed ID: 6491697
[TBL] [Abstract][Full Text] [Related]
39. Phase I clinical study of N-(phosphonacetyl)-L-aspartic acid (PALA).
Valdivieso M; Moore EC; Burgess AM; Marti JR; Russ J; Plunkett W; Loo TL; Bodey GP; Freireich EJ
Cancer Treat Rep; 1980; 64(2-3):285-92. PubMed ID: 7407763
[No Abstract] [Full Text] [Related]
40. Modulation of fluorouracil by N-(phosphonacetyl)-L-asparate: a review.
Martin DS; Kemeny NE
Semin Oncol; 1992 Apr; 19(2 Suppl 3):49-55. PubMed ID: 1557657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]